Advertisement

Journal of Gastrointestinal Cancer

, Volume 48, Issue 3, pp 262–266 | Cite as

Validation of a Liver Index and Its Significance for HCC Aggressiveness

  • Brian I. CarrEmail author
  • Vito Guerra
Original Research
  • 84 Downloads

Abstract

Background

We recently constructed a liver index (LI) from four liver parameters, namely: blood total bilirubin, gamma glutamyl transpeptidase (GGTP), albumin, and platelet levels (a cirrhosis surrogate). We found that the scores for the liver index related significantly to a four-parameter HCC aggressiveness index (maximum tumor diameter, multifocality, percent portal vein invasion, and blood AFP levels).

Aims

To validate the relationship of liver parameters to tumor aggressiveness parameters in a larger, different HCC dataset.

Results

We now confirm these associations in another large HCC cohort. Furthermore, this liver index showed significant trends with the individual HCC aggressiveness parameters.

Conclusions

These results provide further support for the idea that liver microenvironment, as reflected in liver function tests, may relate to HCC behavior.

Keywords

HCC parameters Aggressiveness index Liver function 

Abbreviations

HCC

Hepatocellular carcinoma

AFP

Alpha-fetoprotein

GGTP

Gamma glutamyl transpeptidase

PVT

Portal vein thrombosis

MTD

Maximum tumor diameter

CT

Computerized axial tomography scan

Alb

Albumin

Plts

Platelets

Bil

Bilirubin

Notes

Acknowledgements

No authors have any proprietary or financial interests.

Compliance with Ethical Standards

Disclosures

None.

Grant Support

None.

References

  1. 1.
    Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer. 1985;56:918–28.CrossRefGoogle Scholar
  2. 2.
    Memon K, Kulik LM, Lewandowski RJ, Wang E, et al. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol. 2014;25:1056–66.CrossRefGoogle Scholar
  3. 3.
    Carr BI, Guerra V, Giannini EG, Farinati F, et al. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. Semin Oncol. 2014;41:252–8.CrossRefGoogle Scholar
  4. 4.
    Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512–27.CrossRefGoogle Scholar
  5. 5.
    Carr BI, Guerra VA. Hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology. 2016;90:215–20.CrossRefGoogle Scholar
  6. 6.
    Carr BI, Guerra V, Giannini EG, Farinati F. An HCC aggressiveness index and blood GTP, bilirubin and platelet levels. Integr Oncol. 2016;5(2):172. doi: 10.4172/2329-6771.1000172.CrossRefGoogle Scholar
  7. 7.
    Carr BI, Guerra V, Giannini EG, Farinati F, et al. A liver index and its relationship to indices of HCC aggressiveness. J Integr Oncol. 2016;5:3.Google Scholar
  8. 8.
    Carr BI, Lin CY, Lu SN. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol. 2014;41:415–21.CrossRefGoogle Scholar
  9. 9.
    Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D’Onofrio M, et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103:597–604.CrossRefGoogle Scholar
  10. 10.
    Johnson PJ, Berhane S, Kagebayashi C, Satomura S, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–8.CrossRefGoogle Scholar
  11. 11.
    Kinoshita A, Onoda H, Imai N, Iwaku A. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:52.CrossRefGoogle Scholar
  12. 12.
    Nojiri S, Joh T. Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle. Int J Mol Sci. 2014;15:5163–74.CrossRefGoogle Scholar
  13. 13.
    Bağırsakçı E, Şahin E, Atabey N, Erdal E, Carr BI. Albumin in relation to growth of Hepatocellular Carcinoma. Oncology. 2017; doi: 10.1159/000471807.CrossRefGoogle Scholar
  14. 14.
    Lu SN, Wang JH, Liu SL, Hung CH, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006;107:2212–22.CrossRefGoogle Scholar
  15. 15.
    D'Alessandro R, Refolo MG, Lippolis C, Giannuzzi G, et al. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer. 2014;14:351.CrossRefGoogle Scholar
  16. 16.
    Ma H, Zhang L, Tang B, Wang Y, et al. γ-Glutamyltranspeptidase is a prognostic marker of survival and recurrence in radiofrequency-ablation treatment of hepatocellular carcinoma. Ann Surg Oncol. 2014;21:3084–9.CrossRefGoogle Scholar
  17. 17.
    Carr BI, Pancoska P, Branch RA. Significance of increased serum GGTP levels in HCC patients. Hepato-Gastroenterology. 2010;57:869–74.PubMedGoogle Scholar
  18. 18.
    Pancoska P, Carr BI, Branch RA. Network-based analysis of survival for unresectable hepatocellular carcinoma. Semin Oncol. 2010;37:170–80.CrossRefGoogle Scholar
  19. 19.
    Utsunomiya T, Shimada M, Imura S, Morine Y, et al. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol. 2010;45:146–52.CrossRefGoogle Scholar
  20. 20.
    Hanigan MH, Gallagher HC, Townsend DM, Gabarra V. Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis. 1999;20:553–9.CrossRefGoogle Scholar
  21. 21.
    Toyoda H, Kumada T, Tada T, Sone Y, et al. Tumor markers for hepatocellular carcinoma: simple and significant predictors of outcome in patients with HCC. Liver Cancer. 2015;4:126–36.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Izmir Biomedicine and Genome CenterDokuz Eylul UniversityIzmirTurkey
  2. 2.Department of Clinical TrialsIRCCS de BellisCastellana GrotteItaly

Personalised recommendations